Carrier and Reproductive Risk
KIR-HLA-C
Types maternal KIR and partner HLA-C, an emerging marker studied in implantation failure.
Types maternal KIR against partner HLA-C; an emerging marker whose clinical utility is still under study.
- Specimen
- EDTA blood (both partners)
- Methodology
- PCR-SSO/SSP genotyping
- Category
- Carrier and Reproductive Risk
Pricing is available through your BioBloom portal or on request.
How it works
- 1
Order
Place the order through the BioBloom portal.
- 2
Sample
Collect the sample — EDTA blood (both partners).
- 3
Analysis
Laboratory analysis — PCR-SSO/SSP genotyping.
- 4
Report
Secure report delivered to your clinic through the portal.
What’s in the report
Maternal KIR haplotype (A/B) and partner HLA-C group with the resulting combination.
Research & evidence
Carrier screening established; adjuncts developingCarrier & reproductive risk
Expanded carrier screening is the ACMG-endorsed standard for identifying reproductive risk. Embryo polygenic scoring and immunogenetic adjuncts are active areas of research, best used within a specialist context.
Limitations: KIR-HLA-C is described by researchers in the field as too early for clinical intervention (Moffett 2016), and the ALIFE2 randomised trial found heparin did not improve live birth in inherited thrombophilia with recurrent loss. Embryo polygenic risk scoring has no established clinical utility and is not a routine test.
Read the research
